The Trifolium pratense L. (red clover), which blossoms, leaves and stems can be used as medicines for treatment of burns, skin diseases, diabetes and other diseases. Recently study shown that pratol (7-hydroxy-4-methoxyflavone), an O-methylated flavone in T. pratense has been evaluated to induce melanogenesis in B16F10 melanoma cells. However, the anti-inflammatory effect of pratol has not been reported. In this study, we investigated the effects of pratol on antiinflammation. We also studied the mechanism of action of pratol in LPS-stimulated RAW 264.7 cells. The cells were treated with various concentration of pratol (25, 50, or 100 μM) and 25 μM ammonium pyrrolidinedithiocarbamate (APDC) was used as control. The results in LPS-stimulated RAW 264.7 cells showed that pratol significantly reduced nitric oxide (NO) and prostaglandin E 2 (PGE 2 ) production without any cytotoxic. In addition, pratol strongly decreased the expression of inducible nitric oxide synthase (iNOS) and cyclooygenase (COX-2). Furthermore, pratol reduced proinflammatory cytokines such as tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6. We also found that pratol strongly inhibited activation of nuclear factor kappa B (NF-κB) by reducing the p65 phosphorylation and protecting inhibitory factor kappa B alpha (IκBα) degradation. The results suggest that, pratol may be used to treat or prevent inflammatory diseases such as dermatitis, arthritis, cardiovascular and cancer.
Inflammation is the body's external bacterial pathogens that enter through wounds during physical or chemical injuries [1] . Thus, external body stimulation activates the enzymes and proteins that are involved in the defense mechanism [2] . Inflammatory reactions can heal tissue injury. However, sustained inflammation can cause further damage to tissues and cells and potentially cause cancer [3] .
Macrophages are activated by the presence of bacteria and viruses or by stimulation with external signals. In particular, lipopolysaccharide (LPS), an endotoxin produced by gram-negative bacteria, stimulates macrophages, which in turn activate signaling pathways such as the nuclear factor kappa B (NF-κB) and mitogen activated protein kinase (MAPK) pathways. These signaling pathways promote the secretion of proinflammatory cytokines, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, and induce the expression of inflammatory response factors, such as nitric oxide (NO) and prostaglandin E 2 (PGE 2 ) [4, 5] .
In various mammals, NO is produced from L-arginine via the catalytic action of inducible nitric oxide synthase (iNOS) [6] . Previous studies have indicated that overexpression of inflammatory factors and proinflammatory cytokines is associated with inflammatory diseases, such as rheumatoid arthritis, dermatitis, atherosclerosis, diabetes, and cancer [7] [8] [9] [10] . Cyclooxygenase-2 (COX-2) facilitates the conversion of arachidonic acid from the cell membrane phospholipids of macrophages into prostaglandin, which in turn upregulates PGE 2 expression. PGE 2 overexpression has been shown to participate in tumorigenesis by inhibiting tumor cell apoptosis and inducing angiogenesis [11] [12] [13] [14] .
The NF-κB and MAPK signaling pathways are the primary regulators of inflammatory response factors following LPS stimulation of macrophages, such as RAW 264.7 cells [15] . In its inactive form, NF-κB is normally bound to IκBα in the cytoplasm [16] . Upon LPS stimulation, IκBα is phosphorylated and subsequently degraded, leading to NF-κB release. Subsequently, NF-κB undergoes phosphorylation and translocates to the nucleus, where it acts as a transcription factor to promote the synthesis of iNOS, COX-2, and inflammatory cytokines [17] [18] [19] . Thus, suppression of NF-κB activity can inhibit the expression of inflammatory factors and proinflammatory cytokines. The development of treatment and prevention strategies against inflammatory diseases requires the investigation of compounds that inhibit iNOS and COX-2, which in turn regulate the expression of NO and PGE 2 and inhibit the secretion of inflammatory mediating cytokines, such as TNF-α, IL-1β, and IL-6. Pratol (7-hydroxy-4-methoxyflavone), an O-methylated flavone, was originally isolated from Trifolium pratense L., also known as (red clover) [20] . The flowers, leaves, and stalks of red clover have been used as medicine [21] . In particular, the petals are used in ointments that are mixed with water to treat wounds, burns, cough, and eye diseases; or boiled as tea to relieve fever, cough, and asthma [22] . Studies have demonstrated that pratol can induce melanogenesis in B16F10 melanoma cells [23] . However, the antiinflammatory effects of pratol have not been reported. Therefore, in this study, LPS-stimulated RAW 264.7 cells were treated with various concentrations of pratol to evaluate the effects of pratol on the expression of inflammatory factors and proinflammatory cytokines. Western blot analysis was conducted to confirm the pathways responsible for inhibiting inflammation. (Figure 2 ). These findings showed that the pratol concentrations that were tested did not exert significant cytotoxicity. Therefore, these concentrations were used for subsequent experiments. For the treatment group, RAW 264.7 cells were treated with varying concentrations of pratol (25, 50 , and 100 μM) for 24 h. Control cells were treated with DMEM containing 1 μg/mL LPS and 25 μM APDC. Results revealed that treatment with LPS alone induced NO production. APDC, an NF-κB inhibitor, was found to inhibit NO production by more than 60%. Treatment of LPS-stimulated RAW 264.7 cells with a high concentration of pratol (100 μM) significantly inhibited NO production by at least 45% compared to treatment with LPS alone (Figure 3a) .
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A PGE 2 mouse enzyme-linked immunosorbent assay (ELISA) kit was used to measure PGE 2 production under the same aforementioned conditions. Treatment of LPS-stimulated cells with pratol was found to decrease PGE 2 production in a concentrationdependent manner compared to treatment with LPS alone. A high pratol concentration (100 μM) inhibited PGE 2 production by at least 85%, while decreasing PGE 2 production by more than 5% compared to that observed with APDC treatment. The above results suggested that pratol effectively inhibited PGE 2 production in LPSstimulated RAW 264.7 cells without observed cytotoxicity ( Figure  3b ).
Western blot analysis was performed to determine whether inhibition of NO and PGE 2 production by pratol leads to downregulation of iNOS and COX-2 expression. Results clearly showed that pratol treatment significantly decreased protein levels of iNOS and COX-2 compared to treatment with LPS alone (Figure 4 ). Recent findings showed that LPS-stimulated macrophages showed upregulation of proinflammatory cytokines, such as TNF-α, IL1-β and IL-6, which are known to mediate inflammation. TNF-α is associated with inflammatory skin diseases in humans, and treatment with antibodies targeting TNF-α was demonstrated to alleviate symptoms of various inflammatory diseases and allergies [24] . Rheumatoid arthritis is characterized by the upregulation of cytokines, such as TNF-α and IL-6, which cause neural tissue injury in the human body [25] . Therefore, ELISA was performed to investigate the effects of pratol on the expression of the inflammatory cytokines TNF-α, IL-1β, and IL-6 in RAW 264.7 cells. LPS-stimulated RAW 264.7 cells were treated with various concentrations of pratol (25, 50 , and 100 μM), following which TNF-α, IL-1β, and IL-6 levels were measured. Results confirmed that pratol treatment at the indicated concentrations inhibited the expression of TNF-α, IL-1β, and IL-6 in a concentration-dependent manner, relative to treatment with LPS alone ( Figure 5 ). from the NF-κB complex and is targeted for degradation [26] . We performed western blot to determine whether pratol treatment protects against IκBα degradation. As shown in Fig. 6 , treatment with various concentrations of pratol significantly upregulated IκBα expression compared to treatment with LPS alone. The above results indicated that pratol inhibited the phosphorylation and degradation of IκBα and suppressed the nuclear translocation of phosphorylated NF-κB, thereby suppressing inflammation.
NF-κB is a heterodimer comprising the p50 and p65 subunits. Upon phosphorylation, NF-κB is activated and translocates to the nucleus, where it induces gene expression of iNOS and COX-2, which in turn mediate inflammation [27] . Therefore, we performed western blot analysis to measure phosphorylated p65 levels and examine the effects of pratol on NF-κB activity. As shown in Fig. 7 , pratol significantly decreased p-p65 levels compared to treatment with LPS alone. The above findings showed that pratol markedly alleviated inflammation by inhibiting the p65 phosphorylation and suppressing the NF-κB signaling pathway. In conclusion, our current findings showed that pratol inhibits inflammation in LPS-stimulated RAW 264.7 cells without exerting cytotoxicity. Furthermore, pratol was found to downregulate the expression of the proinflammatory cytokines TNF-α, IL1-β, and IL-6, and effectively inhibit the expression of iNOS and COX-2, which in turn decreased NO and PGE 2 production. Moreover, pratol strongly inhibited NF-κB (p65) phosphorylation and IκBα degradation in the NF-κB pathway, thereby suppressing inflammation in LPS-stimulated RAW 264.7 cells. The above results indicated that pratol could be used for the treatment or prevention of inflammatory diseases. Additionally, pratol can be used in the formulation of sensitive skin care products.
Experimental
Chemicals and Reagents: Pratol was purchased from Extrasynthese (Genay CEDEX, France). DMEM, fetal bovine serum (FBS), penicillin/streptomycin, trypsin-ethylenediaminetetraacetic acid, and BCA kit were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Dimethyl sulfoxide (DMSO), NaOH, MTT, radioimmunoprecipitation assay (RIPA) buffer, and ammonium pyrrolidinedithiocarbamate (APDC) were obtained from SigmaAldrich (St. Louis, MO, USA Cell viability assay: MTT assay was performed to investigate the effects of pratol treatment on cell survival. RAW 264.7 cells were cultured in DMEM containing 1% penicillin and 10% FBS for 24 h. RAW 264.7 cells at 1.5 × 10 5 cells/well were then dispensed onto 24-well plates and cultured for 48 h. After removing the supernatant, MTT reagent (0.5 g/L) was diluted with DMEM, after which each well was added with 400 μL of the mixture and incubated for 3 h. The supernatant was then removed, and DMSO was added to the formazan crystals. The cells were transferred to a six-well plate after incubated for 1 h at 37 °C. The absorbance was measured at 550 nm using a microplate reader (Tecan, Mannedorf, Switzerland).
Measurement of Nitrite (NO) production: RAW 264.7 cells were cultured in DMEM supplemented with 1% penicillin and 10% FBS on a 24-well plate (1.5ⅹ10 5 cells/well) for 24 h. Subsequently, cells
were treated with pratol (25, 50, and 100 μM), LPS (1 μg/mL), and 25 μM APDC in combination. Next, 100 μL of the supernatant was mixed with Griess reagent and added to the wells of a 96-well plate, which was incubated for 1 h under dark conditions. For each sample, the absorbance at 550 nm was measured using a microplate reader.
Measurement of PGE 2 and proinflammatory cytokine production: RAW 264.7 cells were plated on a 24-well plate (1.5ⅹ10 5 cells/well) and cultured for 24 h. Then, cells were treated with 50 μL of LPS (1 μg/mL) and pratol (25, 50 , and 100 μM) for 24 h. Control cells were incubated with only DMEM, only LPS (1 μg/mL), and with a combination of both LPS and 25 μM of APDC. After 24 h, the culture broth was isolated and centrifuged at 10,000 rpm for 3 min. Supernatants were collected for the measurement of PGE 2 , TNF-α, IL-6, and IL-1β levels using a mouse enzyme-linked immunosorbent assay (ELISA) kit.
Western blotting: RAW 264.7 cells were seeded in 100-mm dishes (1.0 × 10 5 cells/well) and cultured for 24 h. Cells were treated with 550 Natural Product Communications Vol. 13 (5) 2018 Chung et al.
various concentrations of pratol (25, 50 , and 100 μM). Control cells were incubated in DMEM containing only LPS (1 μg/mL) or a combination of LPS and 25 μM APDC. Next, the cells were detached via trypsin treatment and lysed by vortexing every 10 min for 1 h in RIPA buffer containing protease inhibitor cocktail (1%). After centrifugation at 13,000 ×g for 20 min, supernatants were collected and proteins were quantified via BCA protein assay. Samples for western blotting were prepared by mixing the proteins with 2× Laemmli sample buffer in a 1:1 ratio, and boiling at 100 °C for 5 min. Each sample was adjusted to achieve a protein concentration of 20 μg. For sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), samples were firstly cooled at 4 °C. Each sample (20 μL) was loaded onto each well, and the gel was set to run for 1 h. Separated proteins were transferred onto a polyvinylidene difluoride membrane. Membranes were blocked for 1 h with 5% non-fat skim milk dissolved in Tris-buffered saline containing 0.4% Tween 20 (TBST). Membranes were incubated for 1 day with primary antibodies dissolved in skim milk (1:1000). After washing with TBST every 10 min for 1 h, membranes were incubated with diluted secondary antibodies (1:3000) for 1 h. Protein bands were detected using an Enhanced Chemiluminescence (ECL) kit.
Statistical analysis:
Experimental results were analyzed using student's t-test. p-values < 0.05 (*) or 0.01 (**) was considered statistically significant. All data were expressed as percentages relative to the control. Reported values were expressed as mean ± SD of at least three independent experiments.
